Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001915 | 0.89 | HPGD (0.49) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21039940 | 0.89 | HPGD (0.49) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL17109787 | 0.88 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL741520 | 0.87 | EPHX1 (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL22284199 | 0.83 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21039941 | 0.83 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL20060955 | 0.83 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21040545 | 0.83 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL4437414 | 0.83 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL22284229 | 0.82 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | HPGD 2111/4885RECQL 910/4885EPHX1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.